slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 7,351-7,380
Pages 395
Rows per page 30
Slide function
7,351-7,380 of 11,828
13
The chart uses a trend line to emphasize the growth trajectory.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Traction1 hit
17
Freightos | Investor Presentation Deck | 35 slidesFreightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Traction1 hit
18
The chart tracks the percentage of bookings placed by forwarder cohorts relative to their initial first-quarter bookings.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Traction1 hit
20
The slide uses a flywheel concept to frame the growth metrics.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Financials1 hit
21
The slide illustrates the dual revenue stream model of the company.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Financials1 hit
22
The slide uses a combination of a grouped bar chart for internal financial performance and a single-series bar chart for competitive benchmarking.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Financials1 hit
23
The slide uses two bar charts to demonstrate improving financial health.Freightos | Investor Presentation Deck | 35 slides · Freightos
Pitch deck Investor relations Beat · Financials1 hit
05
The slide uses a before/after PET scan visual to demonstrate clinical efficacy.Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a process diagram to show the evolution of the FPI-2265 program.Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Solution1 hit
18
Includes medical imaging (SPECT/CT) comparing baseline vs. cold antibody intervention.Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
19
Includes before/after PET-CT scan imagery.Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
The chart shows a clear dose-dependent reduction in tumor volume compared to vehicle and cold antibody controls.Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
09
Slide highlights a strategic partnership/traction milestone.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
10
The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
16
The chart tracks individual patient timelines, including disease progression, partial responses, and study outcomes.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
18
The slide presents two line charts showing tumor volume reduction over time, highlighting 100% complete response (CR) and resistance to tumor rechallenge.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
19
The slide shows two line charts comparing tumor volume reduction across different treatment regimens in mouse models.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
20
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The slide presents two line charts showing tumor volume over time, illustrating the efficacy of THIO in primary treatment and rechallenge scenarios.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
08
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
09
The slide uses a process flow diagram to map clinical outcomes to specific trial metrics.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
This is a citation slide showcasing scientific validation of the company's technology.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
The slide uses a human silhouette as a central diagram to map specific fungal pathogens and resulting conditions to anatomical locations.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Focuses on clinical success in a compassionate use setting.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
19
The slide uses a matrix-like structure to map disease areas (Infection, Inflammation, Oncology) to specific animal models and clinical indications.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
21
The chart shows dose-response curves where LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
22
The slide uses a timeline diagram to explain the experimental design and a line chart to show tumor volume reduction over time.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The study is an ex-vivo human whole blood study using 80 ug/mL LNC and 512 ng/mL Cy5-labeled siRNA cargo.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
26
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit